A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma

详细信息    查看全文

• 作者：Nicole Marie Agostino ; Christine Saraceni ; Hope Kincaid ; Wenjing Shi…
• 关键词：Melanoma ; Stage IV ; Biomarkers ; VEGF ; Tregs ; TH1/TH2 ratio ; CD4+/CD8+ ratio ; LDH
• 刊名：SpringerPlus
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：4
• 期：1
• 全文大小：1725KB
• 参考文献：Abeloff MD, Armitage JO, Neiderhuber JE, Kastan MB, McKenna WG (2008) Abeloff鈥檚 Clinical Oncology, 4th edn. Churchill Livingstone, Philadelphia
  Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R et al (2009) LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 45:1807鈥?4CrossRef
  Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107:2409鈥?4CrossRef
  American Cancer Society (2014). Cancer Facts and Figures. http://鈥媤ww.鈥媍ancer.鈥媜rg/鈥媟esearch/鈥媍ancerfactsstati鈥媠tics/鈥媍ancerfactsfigur鈥媏s2014/鈥?/span> Accessed March 2014
  Atkins MD, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al (1999) High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105鈥?6
  Battaglia A, Buzzonetti A, Martinelli E, Fanelli M, Petrillo M, Ferrandina G et al (2010) Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int J Radiat Oncol, Biol, Phys 76(5):1546鈥?3CrossRef
  Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455鈥?5CrossRef
  Brychtova S, Bezdekova M, Brychta T, Tichy M (2008) The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 55:273鈥?
  Cohen J (1988) Statistical power analysis for the behavorial sciences, 2nd edn. Erlbaum, Hillsdale, NJ
  Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC Cancer Staging Handbook, 7th edn. Springer, New York
  Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010a;363:809鈥?19.
  Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2010b;367:107鈥?14
  Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27鈥?1CrossRef
  Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M et al (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139鈥?7CrossRef
  Hansen W (2013) Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma. OncoImmunology 2:e23039CrossRef
  Hernberg MM, Hahka-Kemppinen MH, Pyrh枚nen SO (2004) The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma. Melanoma Res 14(6):493鈥?00CrossRef
  Hodi FS, O鈥橠ay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711鈥?2CrossRef
  Jiang H, Chess L (2006) Regulation of immune responses by T cells. N Engl J Med 354:1166鈥?6CrossRef
  Kaufman HL, Kirkwood JM, Hodi S, Agarwala S, Amatruda T, Bines SD et al (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588鈥?8CrossRef
  Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P et al (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178鈥?6CrossRef
  Lee CL, Chiu PC, Lam KKW, Siu SO, Chu IK, Koistinen R et al (2011) Differential actions of glycodelin-A on Th-1 and Th-2 cells: a paracrine mechanism that could produce the Th-2 dominant environment during pregnancy. Hum Reprod 26(3):517鈥?6CrossRef
  Lund Research Ltd. Testing for Normality Using SPSS. Laerd Statistics website (2013). Available at https://鈥媠tatistics.鈥媗aerd.鈥媍om/鈥媠pss-tutorials/鈥媡esting-for-normality-using-spss-statistics.鈥媝hp . Accessed on March 24, 2014.
  Milpied P, Renand A, Bruneau J, Mendes-da-Cruz DA, Jacquelin S, Asnafi V et al (2009) Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur J Immunol 39(6):1466鈥?1CrossRef
  Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T et al (2001) Th1-specific cell surface protein Tim-2 regulates macrophage activation and severity of an autoimmune disease. Nature 415:536鈥?1CrossRef
  Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN (2009) Melanoma Study Group of the Mayo Clinic Cancer Center. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 15:1931鈥?CrossRef
  Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Cancer 127:759鈥?7
  Paulos CM, Nelson MH, Xue-Zhong Y (2014) Tumor-Induced Immune Suppression Mechanisms and Therapeutic Reverasal: Th17 Cells in Cancer. Springer, New York
  Perez DG, Suman VJ, Fitch TR, Amatruda T 3rd, Morton RF, Jilani SZ et al (2009) Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 115:119鈥?7CrossRef
  Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477鈥?2
  Piechnik A, Dmoszynska A, Omiotek M, Mlak R, Kowal M, Stilgenbauer S et al (2013) The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer 133:1489鈥?7CrossRef
  Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B et al (2009) Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27:2645鈥?2CrossRef
  Salven P, Teerenhovi L, Joensuu H (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin鈥檚 lymphoma. Blood 90:3167鈥?2
  Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA et al (1993) Prognostic factors in patients with malignant melanoma: a multivariate analysis. Cancer 72:3091鈥?CrossRef
  Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443鈥?4CrossRef
  Warner RM (2008) Alternative Correlation Coefficients. In: Applied Statistics: From Bivariate Through Multivariate Techniques, 1st edn. Sage Publication Inc, Thousand Oaks, CA, pp 309鈥?2
  
• 作者单位：Nicole Marie Agostino (1)
  Christine Saraceni (1)
  Hope Kincaid (1)
  Wenjing Shi (1)
  Wendy Kay Nevala (2)
  Svetomir Markovic (2)
  Suresh G Nair (1)
  
  1. Lehigh Valley Health Network, Department of Hematology Oncology, John and Dorothy Morgan Cancer Center, 1240 S. Cedar Crest Blvd, Suite 401, Allentown, PA, 18103, USA
  2. Mayo Clinic, Rochester, MN, USA
  
• 刊物类别：Science, general;
• 刊物主题：Science, general;
• 出版者：Springer International Publishing
• ISSN：2193-1801

文摘

Background The immune system and vascular endothelial growth factor (VEGF) may be influential in melanoma behavior. We performed a prospective, exploratory analysis in 10 stage III and 22 stage IV melanoma patients to observe factors influencing outcomes.